As of the latest SEC filings, AgomAb Therapeutics NV (AGMB) is held by 10 institutional funds. The largest fund shareholder is Federated Hermes Kaufmann Fund (KAUAX), holding an estimated $10,645,846.40 in market value, representing 0.23% of its portfolio.
Funds holding AgomAb Therapeutics NV (AGMB)
Source: SEC Form N-PORT institutional portfolio disclosures
- Ticker:
- AGMB
- CIK:
- 0002020932
| Fund | Type | Manager | Weight | Market Value | Shares |
Report Date
|
Filing Date
|
|---|---|---|---|---|---|---|---|
|
KAUAX
Federated Hermes Kaufmann Fund
|
MF | Federated Hermes | 0.23% | $10,645,846.40 | 981,184 | Apr 30, 2026 | Jun 23, 2026 |
|
FGCKX
Fidelity Growth Company Fund
|
MF | Fidelity | 0.01% | $8,136,189.54 | 507,877 | Feb 28, 2026 | Apr 24, 2026 |
|
FKASX
Federated Hermes Kaufmann Small Cap Fund
|
MF | Federated Hermes | 0.23% | $6,680,431.80 | 615,708 | Apr 30, 2026 | Jun 23, 2026 |
|
HQH
abrdn Healthcare Investors
|
CEF | abrdn / Aberdeen | 0.27% | $3,051,215.81 | 290,869 | Mar 31, 2026 | May 29, 2026 |
|
THW
abrdn World Healthcare Fund
|
CEF | abrdn / Aberdeen | 0.60% | $2,884,750.00 | 275,000 | Mar 31, 2026 | May 29, 2026 |
|
FGKFX
Fidelity Growth Company K6 Fund
|
MF | Fidelity | 0.01% | $2,294,064.00 | 143,200 | Feb 28, 2026 | Apr 24, 2026 |
|
FCGSX
Fidelity Series Growth Company Fund
|
MF | Fidelity | 0.01% | $2,069,784.00 | 129,200 | Feb 28, 2026 | Apr 24, 2026 |
|
HQL
abrdn Life Sciences Investors
|
CEF | abrdn / Aberdeen | 0.27% | $1,487,345.63 | 141,787 | Mar 31, 2026 | May 29, 2026 |
|
-
Federated Hermes Kaufmann Fund II
|
ETF | Federated Hermes | 0.23% | $221,422.92 | 21,108 | Mar 31, 2026 | May 22, 2026 |
|
FPHAX
Select Pharmaceuticals Portfolio
|
MF | Fidelity | 0.01% | $145,782.00 | 9,100 | Feb 28, 2026 | Apr 24, 2026 |
Advertisement (320x50)